December 12, 2023 PTV-12-23-CL-01
It is widely accepted that stem cell therapies hold great promise in areas like regenerative medicine, disease modeling, and drug discovery. While there are exciting doors opening around these applications, questions remain on the most effective tools and processes to utilize when transitioning promising therapies from the lab bench into the production suite and beyond.
Ben Josey, Ph.D., and Robert Padilla, MS, Field Application Scientists from Corning Life Sciences, discuss considerations and strategies for transitioning stem cell therapies from research into a production environment.
Discussion topics include:
Dr. Ben Josey received his Ph.D. in pharmaceutical and biomedical sciences from the Medical University of South Carolina working on small molecule– and biomaterial-based treatments for cancer and neurodegenerative disease. Dr. Josey has held several positions in academia focused on translational research to overcome immunological barriers facing cell therapies. Dr. Josey works extensively with research and process development groups optimizing assays and cell culture scale-up conditions for viral production and cellular therapeutics.